Antisense & RNAi Therapeutics Market Revenue Drivers Growth Opportunities Supply Chain Analysis and Forecast Research Report Till 2025
“Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025 with CAGR of 8.6% over the future period as the scope and its applications are rising enormously across the globe.”
The global Antisense & RNAi Therapeutics Market research report provides complete insights on industry scope, trends, regional estimates, key application, competitive landscape and financial performance of prominent players. It also offers ready data-driven answers to several industry-level questions. This study enables numerous opportunities for the market players to invest in research and development. Market Overview: Global Antisense & RNAi Therapeutics Market is expected to reach USD 1.81 billion by 2025. RNA therapeutics states to the use of oligonucleotides to target mainly ribonucleic acids (RNA) for research studies to explain functions of genes or therapeutic efforts. Antisense molecules are termed as a synthetic oligodeoxynucleotides (ODN) which are designed in a way that they can hybridize precisely coding mRNA inside the cell. Antisense RNA is always related to RNA interference (RNAi). Key Players:
Olix Pharmaceuticals GlaxoSmithKline Plc Sanofi S.A. Alnylam Pharmaceuticals Isis Pharmaceuticals / Ionis Pharmaceuticals Benitec Biopharma Ltd. Acuitas Therapeutics Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals) Silence Therapeutics Plc